263 related articles for article (PubMed ID: 25697592)
1. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.
Karthaus M; Lehrnbecher T; Lipp HP; Kluge S; Buchheidt D
Ann Hematol; 2015 Apr; 94(4):547-56. PubMed ID: 25697592
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
3. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
Dolton MJ; McLachlan AJ
Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis.
Butler-Laporte G; Langevin MC; Lemieux C; Poirier C; Ferraro P; Théorêt Y; Luong ML
Clin Transplant; 2022 Aug; 36(8):e14709. PubMed ID: 35575963
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of voriconazole serum concentrations and safety profile in pediatric oncology patients].
Silva F; Navea D; Saias C; Torres JP; Catalán P; Morales J
Rev Chilena Infectol; 2016 Apr; 33(2):127-34. PubMed ID: 27314989
[TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.
Cabral-Galeano E; Ruiz-Camps I; Len-Abad O; Pou-Clavé L; Sordé-Masip R; Meije-Castillo Y; Blanco-Grau A; Barba-Suñol P; Monforte-Torres V; Román-Broto A; Pahissa-Berga A; Gavaldà-Santapau J
Enferm Infecc Microbiol Clin; 2015 May; 33(5):298-302. PubMed ID: 25459191
[TBL] [Abstract][Full Text] [Related]
10. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.
Choi SH; Lee SY; Hwang JY; Lee SH; Yoo KH; Sung KW; Koo HH; Kim YJ
Pediatr Blood Cancer; 2013 Jan; 60(1):82-7. PubMed ID: 22887791
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE; Hope WW
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.
Hsu AJ; Tamma PD; Fisher BT
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0215621. PubMed ID: 35766509
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
[TBL] [Abstract][Full Text] [Related]
15. Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?
Danion F; Jullien V; Rouzaud C; Abdel Fattah M; Lapusan S; Guéry R; Bigé N; Morgand M; Pallet N; Lanternier F; Lortholary O
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967027
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.
Encalada Ventura MA; van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2016 May; 60(5):2727-31. PubMed ID: 26883707
[TBL] [Abstract][Full Text] [Related]
17. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.
Martin JM; Macias-Parra M; Mudry P; Conte U; Yan JL; Liu P; Capparella MR; Aram JA
Pediatr Infect Dis J; 2017 Jan; 36(1):e1-e13. PubMed ID: 27636722
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center.
Lindsay J; Krantz EM; Morris J; Sweet A; Tverdek F; Joshi A; Yeh R; Hill JA; Greenwood M; Chen SC; Kong DCM; Slavin M; Pergam SA; Liu C
Transplant Cell Ther; 2022 Aug; 28(8):511.e1-511.e10. PubMed ID: 35623614
[TBL] [Abstract][Full Text] [Related]
19. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.
Zeng G; Wang L; Shi L; Li H; Zhu M; Luo J; Zhang Z
Eur J Clin Pharmacol; 2020 Apr; 76(4):515-523. PubMed ID: 31932875
[TBL] [Abstract][Full Text] [Related]
20. Improvement of the pharmacokinetic/pharmacodynamic relationship in the treatment of invasive aspergillosis with voriconazole. Reduced drug toxicity through novel rapid release formulations.
Gallego-Arranz T; Pérez-Cantero A; Torrado-Salmerón C; Guarnizo-Herrero V; Capilla J; Torrado-Durán S
Colloids Surf B Biointerfaces; 2020 Sep; 193():111119. PubMed ID: 32464356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]